

TEXAS CANCER REGISTRY

Preface

With original authorization from the *1979 Texas Cancer Control Act* and the *Texas Cancer Incidence Reporting Act, (Chapter 82, Health and Safety Code, amended September, 2001) (Appendix B)*, the Texas Cancer Registry (TCR) of the Texas Department of State Health Services (DSHS) collects information on each patient seeking diagnosis and/or treatment for cancer at health care facilities and clinical laboratories, as well as physician and other outpatient offices (in certain circumstances), within the State of Texas. *Chapter 91 of the Texas Administrative Code* (amended July 2006) outlines the rules necessary to implement this act (*Appendix B*). The laws and rules may be accessed at the following web site: www.dshs.state.tx.us/tcr/lawrules.shtm#law.

The mission of the TCR is to collect, maintain, and disseminate high quality cancer data that contribute towards cancer prevention and control, research, improving diagnoses, treatment, survival, and quality of life for all cancer patients. It is estimated that in 2011 there will be 107,111 Texans newly diagnosed with cancer, and another 38,560 will die of the disease. A statewide cancer registry is the foundation for cancer prevention and control. The effectiveness of the Cancer Registry is dependent on complete, timely and accurate reporting.

The TCR is the 4th largest cancer registry in the United States. Approximately 240,000 reports of cancer are received annually from over 500 hospitals, cancer treatment centers, ambulatory surgery centers, and pathology laboratories located throughout the state. The *Texas Cancer Registry Cancer Reporting Handbook, 2011 Edition* serves as the instruction manual to provide rules and guidelines which assure the consistent collection and coding of relevant cancer case information. This edition should be used for reportable cases diagnosed January 1, 2011 and forward. The contents of this manual are based on the guidelines and standards for cancer reporting established by the National Program of Cancer Registries (NPCR); Centers for Disease Control and Prevention (CDC); North American Association of Central Cancer Registries (NAACCR); Surveillance, Epidemiology, and End Results Program (SEER) of the National Cancer Institute (NCI); and the American College of Surgeons (ACoS).

The *TCR Cancer Reporting Handbook, 2011 Edition* will be distributed on compact disc. The handbook can be obtained from the TCR's web site: <http://www.dshs.state.tx.us/tcr/reporting.shtm>. For any problems please contact the TCR. Please remember to monitor the TCR website for training opportunities. The information can be found at <http://www.dshs.state.tx.us/tcr/training.shtm>.

Handbook Sources

The following sources were used in the preparation of this handbook:

- *The SEER Program Coding and Staging Manual 2010*, National Cancer Institute, NIH Pub. No. 10-5581, Bethesda, MD.
- *Standards of the Commission on Cancer Volume II: Facility Oncology Registry Data Standards (FORDS)*. Chicago: American College of Surgeons Commission on Cancer, Revised for 2011.
- *NAACCR Standards for Cancer Registries, Volume II, Data Standards and Data Dictionary, Fifteenth Edition, Record Layout Version 12.1*
- *California Cancer Registry Volume I, Data Standards and Data Dictionary; Cancer Reporting in California: Abstracting and Coding Procedures for Hospitals, Tenth Edition, 2010, Revision 1.0, October 2010*. California Cancer Registry, Public Health Institute.
- *International Classification of Diseases for Oncology. 3rd Edition (ICD-O-3)*. Geneva: World Health Organization, 2000.
- Texas Cancer Incidence Reporting Law (Amended July 2006), Chapter 82, Health and Safety Code and Rules, Title 25, Health Services, Part I. Texas Department of Health, Chapter 91. Cancer, Subchapter A. Cancer Registry (Effective April 24, 2003).
- *SEER*Rx Version 1.5.0. The Cancer Registrar's Interactive Antineoplastic Drug Database*. U.S. Department of Health and Human Services, Public Health Services, National Institutes of Health, Bethesda, MD, 2005
- Collaborative Stage Work Group of the American Joint Committee on Cancer. *Collaborative Stage Data Collection System Coding Instructions, version 02.03.02*. Incorporates updates through January 1, 2011.
- *2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual*, National Cancer Institute, Bethesda, MD 20892-8316
- *Hematopoietic Database Version 1.6.2*, Updated 10/20/2010
- *SEER Inquiry System and Resolved Questions*, web site www.seer.cancer.gov/seer inquiry.
- *Multiple Primary and Histology Coding Rules* January 1, 2007, revised November 5, 2010, National Cancer Institute. Bethesda, MD.

Acknowledgment

We wish to acknowledge that some information presented here was taken verbatim from *The SEER Program Coding and Staging Manual 2010*, Adamo MB, Johnson CH, Ruhl JL, Dickie, LA (eds.). *National Cancer Institute, NIH Publication number 10-5581, Bethesda, MD*. Appendix O is the complete manual for the 2007 Multiple Primary and Histology Rules in text format by the National Cancer Institute's SEER Program with 2010 revisions.

Helpful Websites

www.dshs.state.tx.us/tcr
www.seer.cancer.gov
www.ncra-usa.org
www.naaccr.org
www.cancer.org
www.docboard.org/tx/df/txsearch.htm
www.oralcancerfoundation.org
www.anatomyatlases.org
www.melissa.com
www.pathologyoutlines.com
<http://cancercontrolplanet.cancer.gov>
<http://www.nccn.org/index.asp>
<https://www.medicare.gov/find-a-plan/questions/home.aspx>
<http://www.cdc.gov/niosh/docs/2011-173/>
<http://facs.org/cancer/coc/fordsmanual.html>
<http://www.bls.gov/soc/#material>
www.bcm.edu (Baylor college of medicine)
<http://zip4.usps.com>
www.txhima.org
www.breastcancer.org
www.nlm.nih.gov
www.cancer.gov
www.nci.nih.gov/cancertopics/pdq/cancerdatabase
www.whonamedit.com
<http://www.epa.gov/enviro/html/codes/state.html>
<http://cancerbulletin.facs.org/forums/>

Acronyms

- ACS American Cancer Society
- ACoS American College of Surgeons
- AJCC American Joint Committee on Cancer
- CDC Centers for Disease Control and Prevention
- CESB Cancer Epidemiology and Surveillance Branch
- CNS Central Nervous System
- CoC Commission on Cancer
- CRH *Cancer Reporting Handbook*
- CS Collaborative Stage
- DSHS Texas Department of State Health Services
- FIPS Federal Information Processing Standards
- FORDS *Standards of the Commission on Cancer Volume II: Facility Oncology Registry Data*
- ICD-O-3 *International Classification of Diseases for Oncology, 3rd Edition*
- ICD-O-2 *International Classification of Diseases for Oncology, 2nd Edition*
- MP/H Multiple Primary and Histology Coding Rules
- NAACCR North American Association of Central Cancer Registries
- NPCR National Program of Cancer Registries, CDC
- HSR Health Service Region
- SEER Surveillance, Epidemiology, and End Results Program, NCI
- SINQ SEER Inquiry System, web site: www.seer.cancer.gov/seer inquiry
- TCR Texas Cancer Registry
- WHO World Health Organization
- VSU Vital Statistics Unit

OVERVIEW OF REPORTING CHANGES

NAACCR Record Layout Version

All submissions must be submitted in NAACCR Version 12.1 regardless of diagnosis date.

Data Field Changes

Due to new national cancer reporting standards, changes have been implemented for cases diagnosed on or after January 1, 2011. The following table lists data items which have been revised.

NAACCR Data Item Description	NAACCR Data Item #
*First Name	2240
*Middle Name	2250

*Blanks, spaces, hyphens and apostrophes are now allowed.

Newly Required Data Items for 2011

The following table lists new data items to be reported for 2011.

NAACCR Data Item Description	NAACCR Data Item#
Grade Path Value	441
Grade Path System	449
**Lymph-Vascular Invasion	1182
Reason no Radiation	1430
Comorbid/Complication 1	3110
Comorbid/Complication 2	3120
Comorbid/Complication 3	3130
Comorbid/Complication 4	3140
Comorbid/Complication 5	3150
Comorbid/Complication 6	3160
Comorbid/Complication 7	3161
Comorbid/Complication 8	3162
Comorbid/Complication 9	3163
Comorbid/Complication 10	3164

**Required for Penis (C60) and Testis (C62) only

Newly Required Non Standard Data Items

The following table lists non standard data items to be reported for 2011. These items will be collected for **Breast, Colorectal and Chronic Myeloid/Myelogenous Leukemia only** with noted exceptions. See the Treatment section beginning on page 175 for explanations and instructions for the treatment related data items.

Note: See the table on page 175 for the cases eligible for data collection of non NAACCR standard data items.

Note: Each facility may choose to 1) code and report this information to the TCR, or 2) provide necessary information for the TCR to collect/code the non-standard items for breast, colon/rectum, and CML cases. Please contact your TCR representative with any questions. A

list of contacts can be found on page 21.

Non Standard Data Item Description	Non Standard Data Item Number
Chemo 1 NSC Number	9751
Chemo 2 NSC Number	9752
Chemo 3 NSC Number	9753
Chemo 4 NSC Number	9754
Chemo 5 NSC Number	9755
Chemo 6 NSC Number	9756
Chemo 1 Num Doses Planned	9761
Chemo 2 Num Doses Planned	9762
Chemo 3 Num Doses Planned	9763
Chemo 4 Num Doses Planned	9764
Chemo 5 Num Doses Planned	9765
Chemo 6 Num Doses Planned	9766
Chemo 1 Planned Dose	9771
Chemo 2 Planned Dose	9772
Chemo 3 Planned Dose	9773
Chemo 4 Planned Dose	9774
Chemo 5 Planned Dose	9775
Chemo 6 Planned Dose	9776
Chemo 1 Planned Dose Unit	9781
Chemo 2 Planned Dose Unit	9782
Chemo 3 Planned Dose Unit	9783
Chemo 4 Planned Dose Unit	9784
Chemo 5 Planned Dose Unit	9785
Chemo 6 Planned Dose Unit	9786
Chemo 1 Num Doses Received	9791
Chemo 2 Num Doses Received	9792
Chemo 3 Num Doses Received	9793
Chemo 4 Num Doses Received	9794
Chemo 5 Num Doses Received	9795
Chemo 6 Num Doses Received	9796
Chemo 1 Received Dose	9801
Chemo 2 Received Dose	9802
Chemo 3 Received Dose	9803
Chemo 4 Received Dose	9804
Chemo 5 Received Dose	9805
Chemo 6 Received Dose	9806
Chemo 1 Received Dose Unit	9811
Chemo 2 Received Dose Unit	9812
Chemo 3 Received Dose Unit	9813
Chemo 4 Received Dose Unit	9814
Chemo 5 Received Dose Unit	9815
Chemo 6 Received Dose Unit	9816

Non Standard Data Item Description	Non Standard Data Item Number
Chemo 1 Start Date	9821
Chemo 2 Start Date	9822
Chemo 3 Start Date	9823
Chemo 4 Start Date	9824
Chemo 5 Start Date	9825
Chemo 6 Start Date	9826
Chemo 1 Start Date Flag	9831
Chemo 2 Start Date Flag	9832
Chemo 3 Start Date Flag	9833
Chemo 4 Start Date Flag	9834
Chemo 5 Start Date Flag	9835
Chemo 6 Start Date Flag	9836
Chemo 1 End Date	9841
Chemo 2 End Date	9842
Chemo 3 End Date	9843
Chemo 4 End Date	9844
Chemo 5 End Date	9845
Chemo 6 End Date	9846
Chemo 1 End Date Flag	9851
Chemo 2 End Date Flag	9852
Chemo 3 End Date Flag	9853
Chemo 4 End Date Flag	9854
Chemo 5 End Date Flag	9855
Chemo 6 End Date Flag	9856
Chemo Completion Status	9859
Hormone 1 NSC	9861
Hormone 2 NSC	9862
BRM 1 NSC	9871
BRM 2 NSC	9872
Granulocyte CSF Status	9880
Erythro Growth Factor Status	9881
Thrombocyte Growth Factor Status	9882
Reason Subsq RX as Available	9920
Subsq RX 2 nd Course Date	1660 Note: Data item 1660 is available in NAACCR's <i>Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary, Fifteenth Edition, Record Layout Version 12.1</i> , but is no longer supported by CoC. As a result it is included in CDC CER project-specific data dictionary to highlight its inclusion.
Subsq RX 2 nd Date Flag as Available	9955

Non Standard Data Item Description	Non Standard Data Item Number
Subsq RX 2 nd CRS Surg as Available	9921
Subsq RX 2 nd CRS Rad as Available	9922
Subsq RX 2 nd CRS Chemo as Available	9923
Subsq RX 2 nd CRS Horm, as Available	9924
Subsq RX 2 nd CRS Immunotherapy as Available	9925
Subsq RX 2 nd CRS Oth as Available	9926
Subsq RX 2 nd CRS Trans/End as Available	9927
Subsq RX 2 nd Chemo 1 NSC as Available	9931
Subsq RX 2 nd Chemo 2 NSC as Available	9932
Subsq RX 2 nd Chemo 3 NSC as Available	9933
Subsq RX 2 nd Chemo 4 NSC as Available	9934
Subsq RX 2 nd Chemo 5 NSC as Available	9935
Subsq RX 2 nd Chemo 6 NSC as Available	9936
Subsq RX 2 nd Horm 1 NSC as Available	9941
Subsq RX 2 nd Horm 2 NSC as Available	9942
Subsq RX 2 nd Immunotherapy 1 NSC as Available	9951
Subsq RX 2 nd Immunotherapy 2 NSC as Available	9952
Height Required for Breast, Colorectal, and CML when receiving chemo or other drugs. All other sites/histologies: when available in the source record.	9960
Weight Required for Breast, Colorectal, and CML when receiving chemo or other drugs. All other sites/histologies: when available in the source record.	9961
BCR-ABL Cytogenetic (CML)	9900
BCR-ABL Cytogenetic Date (CML)	9901
BCR-ABL Cytogen Date Flag (CML)	9902
BCR-ABL FISH (CML)	9903
BCR-ABL FISH Date (CML)	9904
BCR-ABL FISH Date Flag (CML)	9905
BCR-ABL RT-PCR Qual (CML)	9906
BCR-ABL RT-PCR Qual Date (CML)	9907
BCR-ABL RT-PCR Qual DtFlg (CML)	9908
BCR-ABL RT-PCR Quant (CML)	9909
BCR-ABL RT-PCR Quant Date (CML)	9910
BCR-ABL RT-PCR Quan DtFlg (CML)	9911
*Tobacco Use Cigarettes	9965
*Tobacco Use Other Smoke	9966

Non Standard Data Item Description	Non Standard Data Item Number
*Tobacco Use Smokeless	9967
*Tobacco Use NOS	9968
*Source Comorbidity	9970

***Required for all sites/histologies**

Required Collaborative Stage Fields:

Selected collaborative stage fields are required for all cases diagnosed January 1, 2004 and after.

Item/Field	NAACCR Data Item#
CS Tumor Size	2800
CS Extension	2810
CS Tumor Size/Ext Eval (for cases diagnosed/admitted 2008 and forward)	2820
CS Lymph Nodes	2830
*CS Lymph Nodes Eval	2840
Regional Lymph Nodes Positive	820
Regional Lymph Nodes Examined	830
CS Mets at DX	2850
*CS Mets Eval	2860

*Newly required in 2011.

Required CS Site Specific Factors

TCR requires the collection of CSv2 data items needed to derive SEER Summary Stage, SSFs for Breast, Brain/CNS/Intracranial, and SSF 25 for applicable sites (schema discriminators). TCR requires, as available, the collection of CSv2 data items needed to derive AJCC-7 TNM Stage.

Schema	Site and Morphology	SSFs
Appendix	C181 (Exclude Carcinoid Tumors and Neuroendocrine Carcinoma)	2, 11
BileDuctsDistal	C240	25 (required for SS 2000)
BilDuctsIntraHepat	C220, C221	10
BileDuctsPerihilar	C240	25 (required for SS 2000)
Bladder	C670-C679	2
Brain, CNSOther, Intracranial Gland	C700, C710-C719, C701, C709, C720-C725, C728, C729, C751, C752, C753	1
Breast	C500-C506, C508, C509	1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 21, 22, 23
BuccalMucosa	C060-C061 (Excludes Malignant Melanoma)	1
Carcinoid Appendix	C181; M8153, 8240-8242, 8246, 8249	2

Schema	Site and Morphology	SSFs
Colon	C180, C182-C189 (Excludes Appendix, Gastrointestinal Stromal Tumor, and Neuroendocrine Tumor)	2, 7, 9, 10
Conjunctiva	C690 (Excludes Retinoblastoma, Malignant Melanoma, Kaposi Sarcoma, Lymphoma)	1
CorpusAdenosarcoma	C540-C543, C548-C549, C559; M8933 (Excludes Placenta, Carcinoma, Carcinosarcoma, Leiomyosarcoma, and Endometrial Stromal Sarcoma)	2, 3
CorpusCarcinoma	C540-C543, C548-C549, C559; M8000-8790, 8980-8981, 9700-9701 (Excludes Placenta, Adenocarcinoma, leiomyosarcoma, and Endometrial Stromal Sarcoma)	2, 3
CorpusSarcoma	C540-C543, C548-C549, C559; M8800-8932, 8934-8974, 8982-9136, 9141-9582 (Excludes Placenta, Adenosarcoma, Carcinoma and Carcinosarcoma)	2, 3
Cystic Duct	C240	25 (required for SS 2000)
EpiglottisAnterior	C101 (Excludes Malignant Melanoma)	1
Esophagus	C150-C155, C158-C159	1
EsophagusGEJunction	C160, C161, C162	1, 25 (25 required for SS 2000)
FloorMouth	C040-C041, C048-C049 (Excludes Malignant Melanoma)	1
GISTAppendix	C181; M8935-8936	11
GISTColon	C180, C182-C189; M8935-8936 (Excludes Appendix)	11
GISTEsophagus	C150-C155, C158-C159; M8935-8936	6
GISTPeritoneum	C480-C482, C488; M8935-8936	5, 10
GISTRectum	C199, C209; M8935-8936	11
GISTSmallIntestine	C170-C173, C178-C179; M8935-8936	6
GISTStomach	C160-C166, C168-C169; M8935-8936	6
GumLower	C031, C062 (Excludes Malignant Melanoma)	1
GumOther	C039 (Excludes Malignant	1

Schema	Site and Morphology	SSFs
GumOther cont'd	Melanoma)	
GumUpper	C030 (Excludes Malignant Melanoma)	1
HeartMediastinum	C380-C383, C388	1
Hematopoietic, Reticuloendothelial, Immunoproliferative, Myeloproliferative, and Myelodysplastic Disease	C420, C421, C424	1
Hypopharynx	C129, C130-C132, C138-C139 (Excludes Malignant Melanoma)	1
LacrimalGland	C695 (Excludes Lymphoma)	25 (required for SS 2000)
LacrimalSac	C695 (Excludes Lymphoma)	25 (required for SS 2000)
LarynxGlottic	C320 (Excludes Malignant Melanoma)	1
LarynxOther	C323, C328-C329 (Excludes Malignant Melanoma)	1
LarynxSubglottic	C322 (Excludes Malignant Melanoma)	1
LarynxSupraglottic	C321 (Excludes Malignant Melanoma)	1
LipLower	C001, C004, C006 (Excludes Malignant Melanoma)	1
LipOther	C002, C005, C008-C009; (Excludes Malignant Melanoma)	1
LipUpper	C000, C003 (Excludes Malignant Melanoma)	1
Lung	C340-C343, C348-C349	1
Lymphoma	M9590-9729 (Except 97003 and 97013), M9823, M9827 (Except C420, C421, C424)	2
LymphomaOcularAdnexa	C441, C690, C695-C696; M9590-9734, 9762, 9820-9837, 9940	2
MelanomaChoroid	C693; M8720-8790	2, 3, 4
MelanomaCiliaryBody	C694; M8720-8790	2, 3, 4, 25 (25 required for SS 2000)
MelanomaConjunctiva	C690; M8720-8790	1, 2
MelanomaIris	C694; M8720-8790	4, 25 (25 required for SS 2000)
MelanomaSkin	C440-C449, C510-C512, C518-C519, C600-C602, C608-C609, C632; M8720-8790	1, 2, 3, 4, 7
MerkelCellPenis	C600-C602, C608-C609; M8247	3

Schema	Site and Morphology	SSFs
MerkelCellScrotum	C632; M8247	3
MerkelCellSkin	C440, C442-C449; M8247	3
MerkelCellVulva	C510-C512, C518-C519; M8247	3, 11
MouthOther	C058-C059, C068-C069 (Excludes Malignant Melanoma)	1
MycosisFungoides	C440-C449, C510-C512, C518-C519, C600-C602, C608-C609, C632; M9700-9701	1
NasalCavity	C300 (Excludes Malignant Melanoma)	1
Nasopharynx	C110-C113, C118-C119 (Excludes Malignant Melanoma)	1, 25 (25 required for SS 2000 for C11 only)
NETColon	C180, C182-C189; M8153, 8240-8242, 8246, 8249	2
NETRectum	C199, C209; M8153, 8240-8242, 8246, 8249	2
NETStomach	C160-C166, C168-C169; M8153, 8240-8242, 8246, 8249	1
Oropharynx	C090-C091, C098-C099, C100, C102-C104, C108-C109 (Excludes Malignant Melanoma)	1
PalateHard	C050 (Excludes Malignant Melanoma)	1
PalateSoft	C051-C052 (Excludes Malignant Melanoma)	1
ParotidGland	C079	1
Penis	C600-C602, C608-C609 (Excludes Malignant Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, Other Lymphomas)	17
Peritoneum	C481-C482, C488; M8000-8934, 8940-9136, 9141-9582, 9700-9701 for males; 8580-8589, 8680-8921, 9120-9136, 9141-9582, 9700-9701 for females (Excludes GIST and Peritoneum Female Genital, M8000-8576, 8590-8671, 8930-8934, 8940-9110)	1, 25 (both required for SS 2000)
PeritoneumFemalGen	C480-C482, C488 (Include Carcinoma of Peritoneum for females only)	25 (required for SS 2000)

Schema	Site and Morphology	SSFs
PharyngealTonsil	C111 (Excludes Malignant Melanoma)	1, 25 (25 required for SS 2000)
Placenta	C589	1
Pharynx	C140, C142, C148	1
Pleura	C384 (Includes Pleural Mesothelioma)	1 (required for SS 2000)
Prostate	C619	1, 3, 8, 10
Rectum	C199, C209 (Excludes GIST and Neuroendocrine Tumors)	2, 5, 7, 9, 10
Retinoblastoma	C690-C696, C698-C699; M9510-9514	1 (required for SS 2000)
Retroperitoneum	C480	1
SalivaryGlandOther	C081, C088-C089	1
SinusEthmoid	C311 (Excludes Malignant Melanoma)	1
SinusMaxillary	C310 (Excludes Malignant Melanoma)	1
Skin	C440, C442-C449; SkinScrotum C632 (Excludes Skin of Eyelid, Malignant Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, Other Lymphomas)	12, 16
SkinEyelid	C441	6
SmallIntestine	C170-C173, C178-C179 (Excludes GIST and Neuroendocrine Tumors)	2
Soft Tissue	C470-C476, C478-C479, C490-C496, C498-C499; M8800-8936, 8940-9136, 9141-9582	1
Stomach	C161-C166, C168-C169 (Excludes GIST and Neuroendocrine Tumors)	1, 25 (25 required for SS 2000)
SubmandibularGland	C080	1
Testis	C620-C621, C629	4, 5, 7, 9, 10, 13, 15, 16
TongueAnterior	C020-C023, C028-C029 (Excludes Malignant Melanoma)	1
TongueBase	C019, C024 (Excludes Malignant Melanoma)	1
Vulva	C510-C512, C518-C519 (Excludes Malignant Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, Mycosis Fungoides,	11

Schema	Site and Morphology	SSF's
Vulva cont'd	Sezary Disease, Other Lymphomas	

New Derived Data Items

The following table lists new required data items that will be derived based on other coded fields.

Item/Field	NAACCR Data Item#
Derived AJCC-7 T	3400
Derived AJCC-7 T Descriptor	3402
Derived AJCC-7 N	3410
Derived AJCC-7 N Descriptor	3412
Derived AJCC-7 M	3420
Derived AJCC-7 M Descriptor	3422
Derived AJCC-7 Stage Group	3430
NBCCEDP Linkage Results (breast and cervical)	9980
NBCCEDP Linkage Date (breast and cervical)	9981

Additional Data Items to Include in Transmission as Available

CoC-Approved Registries are required to collect Clinical TNM data items. In 2011 TCR requires that the following items be transmitted when submitting data.

Item/Field	NAACCR Data Item#
TNM Clinical T for Female Breast; Rectum	940
TNM Clinical N for Female Breast; Rectum	950
TNM Clinical M for Female Breast; Rectum	960
TNM Clinical Stage Group for Female Breast; Rectum	970
TNM Clinical Descriptor for Female Breast; Rectum	980
TNM Edition Number for Female Breast; Rectum	1060

Coding Cancer Cases

For cancer coding, the correct ICD-O version must be used for all cases according to the year in which the cancer case was diagnosed. If the diagnosis year is unknown use the year in which the case was accessioned. If this process is not applied the cancer case will fail required edits and will not be accepted by the TCR.

The *International Classification of Diseases for Oncology, 3rd Edition* (ICD-O-3) **must** be used to code the primary cancer site (topography) and the cell type (morphology, behavior, and grade, NAACCR items 522 and 523) of the tumor for all cases diagnosed/admitted on January 1, 2001 and forward. In 2010 several newly reportable conditions and new ICD-O histology terms and codes for

For all cases diagnosed on January 1, 1992-December 31, 2000, the *International Classification of Diseases for Oncology, 2nd Edition* (ICD-O-2) **must** be used to code the primary cancer site (topography) and the cell type (morphology, behavior and grade, NAACCR item 420 and 430).

Staging Cancer Cases

For staging cancer cases, all cases must be staged and the corresponding stage data fields must be completed according to the correct staging guidelines for the year in which the cancer was diagnosed. If the diagnosis year is unknown, the correct guidelines for the year in which the case is accessioned must be used. Otherwise, the cancer case will fail required edits and will not be accepted by the TCR.

Year of Diagnosis	Stage System/Manual
Prior to 2001	<i>SEER April 1977 Summary Staging Guide</i>
January 1, 2001 - December 31, 2003	<i>SEER Summary Staging Manual 2000 (SSSM2K)</i>
January 1, 2004 and forward	<i>Collaborative Stage Data Collection System Coding Instructions, version 02.03.02</i>

Note: Both Collaborative and Summary Stage schemas use all information (both clinical and pathological assessments) available through completion of surgery (ies) in the first course of treatment or within four months of date of diagnosis in the absence of disease progression, whichever is longer.

TCR Coding and Staging Requirement Summary

Coding and Staging Schema	Diagnosis Year
<i>International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3)</i>	2001 – forward
<i>International Classification of Diseases for Oncology, 2nd Edition (ICD-O-2)</i>	1995 – 2000*
<i>Collaborative Stage Data Collection System Coding Instructions, vs. 02.03.02</i>	2004 – forward
<i>SEER Summary Staging Manual 2000 (SSSMK2)</i>	2001 – 2003
<i>SEER April 1977 Summary Staging Guide</i>	1995 – 2000*
<i>Multiple Primary and Histology Coding Rules (MP/H)</i>	2007 - forward
<i>2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual</i>	2010 - forward

*The TCR no longer requires reporting of cases diagnosed prior to 1995.

ACoS FACILITY INSTRUCTION MANUALS AND DATE IMPLEMENTED

Manual/Guidelines	Implemented
Data Acquisition Manual (DAM)	1995
Registry Operations and Data Standards (ROADS)	1996 – 2002
Facility Oncology Registry Data Standards (FORDS)	2003
Collaborative Staging (CS)	2004
Multiple Primary and Histology Coding Rules (MP/H)	2007
2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual	2010

Note: Per SEER, the new coding and staging instructions/guidelines replace the old for respective time periods.

Compliance

To assure timely and complete cancer case reporting in Texas, the TCR monitors compliance with the Texas Cancer Incidence Reporting Act. The TCR health service regions routinely monitor facility submissions of case reports. If submissions are not received complete and in a timely manner according to our current law and rules, the facility registrar/reporter will be contacted regarding the delinquent reporting status. Further action, which may include cost recovery procedures, will be instituted if submissions continue to be delinquent. These actions are necessary to meet the state and national requirements for timely cancer data. To be compliant with the law, **all records must be submitted within 6 months of initial diagnosis, or admission with active disease, or treatment for cancer at your facility.** Cancer reporting rules require quarterly submissions from health care facilities with an annual caseload of 400 or fewer and monthly submissions for health care facilities with an annual caseload greater than 400. Monthly reporting is recommended for all reporters.

Case Submission Requirements:

Caseload	Submission
Equal to or <400	Quarterly
>400	Monthly

Small Cancer Caseload Facilities (100 or fewer):

The TCR developed the “Small Facility Casefinding and Data Collection Program” with the goal to increase and improve the reporting and data quality of cancer cases, as required by the Texas Cancer Incidence Reporting Act (Chapter 82, Texas Health and Safety Code), from Texas facilities with 100 or fewer expected cancer cases. Contracted CTRs and/or TCR staff conduct the casefinding and data collection activities for these facilities. Each year this program is contingent on the availability of funds. Facilities should contact their respective TCR representative to inquire about their facility’s compliance and eligibility for participation in this program. Refer to page 21 for the appropriate regional contact information.

This page left blank